NCT02286154View on ClinicalTrials.gov

Therapeutic Response Evaluation and Adherence Trial (TREAT)

NAActive, not recruitingINTERVENTIONAL

Enrollment

150

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Anemia, Sickle Cell

Interventions

DRUG

Hydroxyurea

For New Cohort participants, PK/PD data will be used to predict the most effective maximum tolerated dose. Old Cohort participants will receive hydroxyurea escalated to MTD as per local clinical guidelines.

Trial Locations (1)

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

All Listed Sponsors

lead

Children's Hospital Medical Center, Cincinnati

OTHER

NCT02286154 - Therapeutic Response Evaluation and Adherence Trial (TREAT) | Biotech Hunter | Biotech Hunter